Search by keyword.
Antibody-drug conjugates (ADCs) combine the targeting capabilities of monoclonal antibodies with the potent cytotoxic effects of small molecule drugs, offering precise targeting of cancer cells while minimizing off-target effects. At SpiroChem, we specialize in all the chemistry aspects of ADCs, focusing on linker and payload optimization to enhance the therapeutic potential of these powerful biopharmaceuticals.
We create linker-payload constructs that are ready-for-ligation, ensuring seamless integration into our clients' development pipelines.
In linker optimization, we focus on properties such as stability, release mechanisms, and biocompatibility to ensure the therapeutic efficacy and safety of ADCs. Our payload optimization involves enhancing the potency and selectivity of the cytotoxic agents to maximize their impact on target cells while minimizing side effects.
Our expertise also extends to developing efficient synthetic strategies to minimize the number of steps in high-potent territory, facilitating scale-up and production. We work on both discovery programs aiming to optimize the properties of resulting ADCs and on synthetic strategies to improve manufacturing efficiency.
Whether working on discovery programs aiming to optimize the properties of resulting ADCs or on synthetic strategies to minimize the number of steps and facilitate scale-up in high-potent territories, we ensure efficiency and precision. Our dedicated team of scientists works diligently to overcome the complexities of ADC development, providing comprehensive support and innovative solutions at every stage.
Get in touch
